SindhuCherianMD

Pathology • Seattle, WA

Hematopathology, Anatomic Pathology, Clinical Pathology

Physician

Join to view full profile

Dr. Cherian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cherian's full profile

Already have an account?

Office
1959 Ne Pacific St
Seattle, WA 98195
Phone+1 206-606-7123

Education & Training

University of Pennsylvania Health SystemFellowship, Hematopathology, 2004 - 2005
University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2001 - 2004
University of Pennsylvania Health SystemInternship, Internal Medicine, 2000 - 2001
Emory University School of MedicineClass of 2000

Certifications & Licensure

WA State Medical License 2005 - 2025
PA State Medical License 2001 - 2006
American Board of Pathology Clinical Pathology
American Board of Pathology Hematology

Publications & Presentations

PubMed

8 citations
Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid
Keith R. Loeb, Sindhu Cherian, Pamela S. Becker, Roland B. Walter, John M. Pagel
British Journal of Haematology. 2016-01-01
725 citations
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Kevin A. Hay, Laila-Aicha Hanafi, Daniel Li, Juliane Gust, W. Conrad Liles
Blood. 2017-11-23
10 citations
Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis
Sindhu Cherian, Vivian McCullouch, Valerie Miller, Katy Dougherty, Jonathan R. Fromm
Cytometry. Part B, Clinical Cytometry. 2016-07-01

Lectures

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

In Hematopathology, Online Learning Mirrors PracticeJuly 23rd, 2024